Enabling the company to help expand accelerate its emerging markets growth.

Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets Further strengthening its global competitive position, Abbott announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical items that Abbott will commercialize in 15 emerging marketplaces, enabling the company to help expand accelerate its emerging markets growth. Abbott also announced the formal creation of a stand-alone Established Items Division concentrated on growing the marketplace for Abbott’s founded pharmaceutical portfolio beyond the U online pharmacy .S., particularly focused in emerging markets.

‘Additionally, with these data, we continue to be on monitor to begin main regulatory submissions in the second quarter of 2014. AbbVie will continue steadily to disclose additional complete phase III study results at upcoming scientific congresses and in publications.’.. AbbVie’s PEARL-III study meets major, secondary endpoints in sufferers with chronic GT1b HCV infection The first detailed results from AbbVie's pivotal stage III study, PEARL-III, were presented today within the 21st Conference on Retroviruses and Opportunistic Attacks press meeting and can also be presented as a late-breaker in the conference on March 4.